01—Abstract
Summary
Summary of the 10-Q filed August 5, 2026. Cited figures are marked; the original filing is the authoritative source.
Exelixis, Inc. reported strong second-quarter 2026 results, with total revenues of $628.7 milliona, up from $568.3 million in the second quarter of 2025, and net income of $212.1 million, or $0.82 per diluted share, compared with $184.8 million, or $0.65 per diluted share, a year earlier.
Net product revenues were $573.0 millionb, driven by CABOMETYX, which generated $570.6 million in the quarter. Research and development expenses were $212.0 million and selling, general and administrative expenses were $147.6 million, with SG&A rising in part on pre-launch marketing for zanzalintinib. Cash, cash equivalents and marketable securities totaled $1.38 billion at June 30, 2026, down from $1.66 billion at December 31, 2025, as the company returned capital through stock repurchases.
Repurchases under the two stock repurchase programs totaled $902.2 millionc through June 30, 2026, with about $597.8 million remaining under the May 2026 program. Management states that current cash and cash equivalents and marketable securities, together with product and collaboration revenues, will fund operations for at least 12 months. The filing highlights ongoing pipeline and regulatory events.
Zanzalintinib, in combination with atezolizumab, is under FDA review for previously treated metastatic colorectal cancer with a PDUFA target action date of December 3, 2026. The STELLAR-303 final overall survival analysis in the non-liver metastases subpopulation was not statistically significant. The company also disclosed multiple Paragraph IV patent challenges to CABOMETYX from generic and 505(b)(2) filers, and the filing notes that the sale of competing cabozantinib products before patent expiration could materially harm the business.
02—Key points
Key Highlights
- Total revenues rose to $628.7 million in Q2 2026 from $568.3 million in Q2 2025; net product revenues were $573.0 million, of which CABOMETYX contributed $570.6 million.
- Net income was $212.1 million ($0.82 per diluted share) in Q2 2026, compared with $184.8 million ($0.65 per diluted share) in Q2 2025.
- Six-month operating cash flow was $559.6 million, versus $260.4 million in the prior-year period, aided by a federal cash tax benefit tied to the One Big Beautiful Bill Act.
- Cash, cash equivalents and marketable securities fell to $1.38 billion at June 30, 2026 from $1.66 billion at December 31, 2025, reflecting $902.2 million of cumulative share repurchases under the October 2025 and May 2026 programs.
- Approximately $597.8 million remained available under the May 2026 stock repurchase program, which runs through December 31, 2027.
- Zanzalintinib plus atezolizumab for previously treated metastatic colorectal cancer is under FDA standard review with a PDUFA target date of December 3, 2026; STELLAR-304 top-line results are expected in the second half of 2026.
- Multiple generic and 505(b)(2) applicants have filed Paragraph IV challenges to CABOMETYX patents, and the FDA granted tentative approval to Handa's 505(b)(2) NDA on July 29, 2026.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in Q2 FY2027, Exelixis kept $0.34.
- Revenue$628.7M100.0%
- Cost of revenue−$20.7M3.3%
- Gross profit$608.0M96.7%
- Operating costs−$359.6M57.2%
- Operating income$248.4M39.5%
- Interest, other & tax−$36.4M5.8%
- Net income$212.1M33.7%
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2027filed August 5, 2026Financial Statements
Q2 FY2027 against Q2 FY2026
| Line item | Q2 FY2027Q2 FY2026 | Change |
|---|---|---|
| Revenue | $628.69M$568.26M | +10.6% |
| Cost of Revenue | $20.66M$19.47M | +6.1% |
| Gross Profit | $608.03M$548.79M | +10.8% |
| R&D Expenses | $211.99M$200.36M | +5.8% |
| SG&A Expenses | $147.63M$134.86M | +9.5% |
| Operating Expenses | $380.28M$354.69M | +7.2% |
| Operating Income | $248.41M$213.58M | +16.3% |
| Net Income | $212.05M$184.85M | +14.7% |
| EPS (Basic) | $0.85$0.68 | +25.0% |
| EPS (Diluted) | $0.82$0.65 | +26.2% |
| Shares Outstanding (Basic) | 250.81M272.58M | −8.0% |
| Shares Outstanding (Diluted) | 259.68M284.39M | −8.7% |
05—Questions
Frequently Asked Questions
How strong was Exelixis's revenue growth and profitability in the second quarter of 2026?
Total revenues were $628.7 million, compared with $568.3 million in the second quarter of 2025, and net income was $212.1 million, or $0.82 per diluted share, versus $184.8 million, or $0.65 per diluted share, a year earlier. Net product revenues were $573.0 million, up from $520.0 million, driven primarily by CABOMETYX.
What is driving the company's product revenue?
The filing attributes the increase in net product revenues to a 6% rise in CABOMETYX units sold and increases of 4% and 3% in average net selling price, reflecting demand for CABOMETYX in combination with nivolumab for first-line advanced RCC and for previously treated advanced NET. Longer treatment duration with the combination also drove refills.
How much cash does Exelixis have, and how is it being used?
Cash, cash equivalents and marketable securities were $1.38 billion at June 30, 2026, compared with $1.66 billion at December 31, 2025. The decline was mainly due to share repurchases, with $753.3 million of payments for repurchases in the first six months of 2026, alongside spending on development and discovery programs. Management believes current resources will support operations for at least 12 months.
What are the key regulatory and pipeline catalysts mentioned in the filing?
The FDA is reviewing an NDA for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, with a PDUFA target action date of December 3, 2026. The STELLAR-304 phase 3 trial in nccRCC is expected to report top-line results in the second half of 2026, depending on event rates.
What legal risks could affect CABOMETYX sales?
Several companies, including MSN, Azurity, Handa, Accord and Almatica, have filed ANDA or 505(b)(2) applications with Paragraph IV certifications, and Exelixis has filed patent infringement suits in response. The filing states that the sale of competing cabozantinib products significantly before CABOMETYX's patent expiration could materially reduce U.S. CABOMETYX revenues. The filing also notes that it is not possible at this time to determine the likelihood or amount of an unfavorable outcome.
06—Continue